Monomeric C-reactive protein - A key molecule driving development of Alzheimer's disease associated with brain ischaemia? by Slevin, Mark et al.
1Scientific RepoRts | 5:13281 | DOi: 10.1038/srep13281
www.nature.com/scientificreports
Monomeric C-reactive protein-a 
key molecule driving development 
of Alzheimer’s disease associated 
with brain ischaemia?
Slevin M.1,2,3, Matou S.1, Zeinolabediny Y.1, Corpas R.9, Weston R.1, Liu D.1, Boras E.1, Di 
Napoli M.4, Petcu E.3, Sarroca S.9, Popa-Wagner A.5, Love S.6, Font M.A.10, Potempa L.A.7, 
Al-baradie R.8, Sanfeliu C.9, Revilla S.9, Badimon L.10 & Krupinski J.11
Alzheimer’s disease (AD) increases dramatically in patients with ischaemic stroke. Monomeric 
C-reactive protein (mCRP) appears in the ECM of ischaemic tissue after stroke, associating with 
microvasculature, neurons and AD-plaques, Aβ, also, being able to dissociate native-CRP into 
inflammatory, mCRP in vivo. Here, mCRP injected into the hippocampal region of mice was 
retained within the retrosplenial tract of the dorsal 3rd ventrical and surrounding major vessels. 
Mice developed behavioural/cognitive deficits within 1 month, concomitant with mCRP staining 
within abnormal looking neurons expressing p-tau and in beta-amyloid 1-42-plaque positive regions. 
mCRP co-localised with CD105 in microvessels suggesting angiogenesis. Phospho-arrays/Western 
blotting identified signalling activation in endothelial cells and neurons through p-IRS-1, p-Tau and 
p-ERK1/2-which was blocked following pre-incubation with mCRP-antibody. mCRP increased vascular 
monolayer permeability and gap junctions, increased NCAM expression and produced haemorrhagic 
angiogenesis in mouse matrigel implants. mCRP induced tau244–372 aggregation and assembly in 
vitro. IHC study of human AD/stroke patients revealed co-localization of mCRP with Aβ plaques, 
tau-like fibrils and IRS-1/P-Tau positive neurons and high mCRP-levels spreading from infarcted core 
regions matched reduced expression of Aβ/Tau. mCRP may be responsible for promoting dementia 
after ischaemia and mCRP clearance could inform therapeutic avenues to reduce the risk of future 
dementia.
The incidence of dementia increases several-fold after acute ischaemic stroke1,2. There is strong evidence 
that brain ischaemia increases the risk of both vascular dementia and Alzheimer’s disease (AD). Most 
risk factors for brain ischaemia and stroke probably increase the risk of AD3. The reasons for this have 
not been clearly identified, but one possible contributor is the inflammatory response to brain ischaemia, 
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with inflammatory mediators contributing significantly to subsequent brain damage in both AD and 
stroke4.
C-reactive protein (CRP) is pentraxin produced mainly by the liver, circulating elevated levels of 
which are significantly associated with AD pathophysiology, and in addition, where affected brain 
regions including neurons have been shown to synthesise this protein de novo5,6. There are two dis-
tinct isoforms of CRP. Native CRP is a pentameric oligoprotein and acute phase reactant, produced 
during active inflammatory disease at physiological circulating levels of between 40–200 μ g/ml7. Unlike 
other pentraxins, native CRP can be dissociated irreversibly to form free sub-units or monomeric CRP 
(mCRP) which has much lower aqueous solubility, becomes tissue ECM-associated and has been shown 
to accumulate within tissue regions of vascular damage/inflammation, particularly, in reference to this 
work, accumulating in active brain neo-microvessels after ischaemic stroke8. This gives CRP unique 
properties amongst the pentraxin family. mCRP is strongly angiogenic both in vitro and in vivo and is 
likely to contribute to the neovascularisation of tissues in which it is deposited or synthesised9.
The production and characterization of antibodies capable of distinguishing between native CRP and 
mCRP has helped enormously in allowing us to identify biologically active mCRP in tissues10. To this 
end, recently, Strang et al.11 demonstrated that Aβ plaques generated in vitro, could dissociate nCRP into 
mCRP thus potentiating inflammatory micro-environments and promoting progression of the disease. 
There is strong support for the theory recently elaborated on by Marchesi et al.4 suggesting that the earli-
est pathological process in AD may be oxidative inflammatory damage to cerebral microvessels, provoked 
by peri-capillary accumulation of Aβ , leading to cerebral amyloid angiopathy (CAA) and stroke, further 
production of Aβ , neuronal dysfunction and damage. In support of this, Bulbarelli et al.12 demonstrated 
recently Aβ (42) microangiopathy and Aβ PP in rat brain EC exposed to glucose-oxygen deprivation, de 
novo synthesis of Aβ peptides by damaged brain microvessels and intracellular deposition may be a key 
event in developing Cerebral Amyloid Angiopathy (CAA). As yet, there is no definitive data or published 
work describing the effects of mCRP on neuronal function and health.
We were interested in the contribution of mCRP to the progression of AD in association with inflam-
mation. Based on our previous findings that large quantities of mCRP are deposited in damaged brain 
regions from the circulation via compromised vasculature after stroke8, we hypothesised that this could 
contribute to pathological neurodegeneration. In this study, we provide strong evidence of a mechanism 
for dysfunctional vascular development and neuronal activation associated with mCRP. This could have 
implications concerning both vascular and neuronal degeneration, linked with neurodegenerative pro-
cesses and in particular vascular dementia/CAA.
Materials and Methods
Monomeric and native CRP source. Recombinant forms of both mCRP and nCRP (0.5 mg/mL in 
25 mM NaPBS, pH 7.4) was produced in the laboratory of Dr. L.A. Potempa as previously described8–10,13. 
The mCRP solution contained an endotoxin concentration lower than 0.125 EU/mL and all cell culture 
medium was endotoxin-free.
Antibodies to mCRP and nCRP. Mouse monoclonal antibodies to human nCRP (N2C10), and the 
octapeptide of the mCRP sub-unit (M8C10) were obtained from Dr L.A. Potempa and fully character-
ized as described previously8.
Cell culture. Bovine aortic endothelial cells (BAEC) were isolated as previously described by Sattar 
et al.14. BAEC were seeded in 75-cm2 flasks pre-coated with 0.1% gelatin (Sigma, UK) and cultured in 
Dulbecco’s Modified Eagle Medium (Lonza, UK) supplemented with 20% foetal bovine serum (FBS, 
Cambrex, UK), 2 mM glutamine and 1% antibiotics (100 μ g/ml streptomycin, 100 U/ml penicillin). 
BAEC were placed at 37 °C in a saturated air humidity/5% CO2-incubator. Every 2–3 days, the cells 
were detached by enzymatic digestion with 0.05% trypsin/0.02% EDTA and split at a ratio of 1:2 or 1:3. 
At confluence, EC were identified by their typical cobblestone morphology and “hill and valley” config-
uration, respectively. The cells were used throughout the study between passages 4 and 9. Rat cortical 
neurons (RCN) were obtained from Life Technologies (UK) and cultured directly into T-25 flasks. These 
were used at the same cell concentration and under the same conditions as BAEC, and according to the 
manufacturer’s instructions.
MatrigelTM endothelial tube formation assay. BAEC (1.5 × 106 cells/ ml) were mixed in equal vol-
ume with growth factor-reduced MatrigelTM (10 mg/ml) with or without 5 μ g/ml mCRP, and a spot of 
the mixture was poured into the centre of each well in a 48-well plates (Nunc). After polymerization 
of the gel for 1 h at 37 °C, each spot of cells embedded in MatrigelTM was bathed in 500 μ l of complete 
medium. After 24 h incubation, some cells migrated and aligned to form tubes (defined by the enclosure 
of circumscribed areas), a parameter of quantification15. For the counting of enclosed areas, the cells were 
fixed with 4% PFA for 15 min and counts made in five fields by microscopy using the × 20 objective. 
Using the same experimental procedure described above, BAEC were mixed with anti-mCRP antibodies 
(1 μ g/ml) at the same time as matrigel and mCRP (5 μ g/ml) to assess if the antibody was capable of 
blocking mCRP-induced angiogenesis. Experiments were repeated three times and results are shown as 
mean ± S.D. (*p < 0.05)
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Spheroid sprouting assay for junctional analysis by T.E.M. The preparation of BAEC spheroids 
was performed as described previously15. Briefly, cells were harvested from sub-confluent monolayer 
cultures by trypsinization and 6 × 105 cells were suspended in DMEM 10% FBS and 0.25% (w/v) carbox-
ymethylcellulose (Sigma, UK). Cells were then seeded into non-adherent round-bottom 96-well plates 
to assemble into a single spheroid within 24 h at 37 °C, 5% CO2. Basic fibroblast growth factor (human 
recombinant FGF-2, (BD Bioscience, UK)) was used as positive control and added at a final concentra-
tion of 25 ng/ml. After 24 h, gels were photographed and sprouting architecture was assessed microscop-
ically. Experiments were performed in triplicate.
Endothelial cell permeability assay. BAEC were cultured to confluence on Transwell collagen 
coated permeable (pored) supports (Millipore) and medium replaced with SPM (24 h). mCRP (10 μ g/ml) 
or DMSO (1 μ g/ml; positive control) was added and cells incubated at 37 °C for a further 8 h. Next, the 
medium was refreshed and replaced with 500 μ l of basal medium and a solution of FITC-dextran (150 μ l; 
1:20 added to each well and incubation continued at room temperature for a further 4 h. The quantity 
of FITC-dextran passing through the pores of the insert into the collecting plate was proportional to the 
permeability of the monolayer. 100 μ l of the collecting medium was read on a fluorescent plate reader 
with filters at 485 and 535 nm excitation and emission according to the manufacturer’s instructions. 
Photomicrographs of the monolayers stained with Millipore cell stain (10 minutes) were also obtained. 
Each test was performed in triplicate and the experiment performed twice, a representative example is 
shown and p < 0.01 is indicated by *).
Mouse matrigel implant. In this pilot study (n = 3 per group), aliquots of growth factor reduced 
matrigel (400 μ l) were injected into C57BL/6 mice subcutaneously at the dorsal surface,+ /− addi-
tion of VEGF (positive control 10 μ g/ml) or nCRP/mCRP (10 μ g/ml). After 5 days, the animals were 
euthanized and plugs dissected and photographed in order to identify evidence of vascularization and 
neo-circulation. Simple statistical analysis (mean ± S.D. was used to count the numbers of vessels asso-
ciated with each implant. Detailed histological analysis of the plugs was not carried out.
Short-Interfering RNA (siRNA) targeting IRS-1. Short-interfering RNA duplexes targeting bovine 
IRS1 (IRS1 siRNA) and negative control (NC siRNA) were selected and chemically synthesised by 
GenePharma (Shanghai, China). Their sequences were:
5′ GCGGUAGUGGCAAACUCUUTT 3′ (sense) 5′ AAGAGUUUGCCACUACCGCTT 3′ (anti-sense)
To examine the transfection efficiency of Lipofectamine2000 (Invitrogen), NC-FAM (negative 
control-fluorescein amino-modified oligonucleotides) siRNA was transfected into BAEC previously 
seeded on glass coverslips, and the following day the cells were washed with PBS, fixed with 4% PFA and 
visualised with a Zeiss fluorescent microscope. For mRNA ‘knock-down’, the reverse transfection method 
was applied as described by Elbashir et al.16. Briefly, the siRNA duplexes were transfected into 70–80% 
confluent BAEC cultured in a 24-well plate at a final concentration of 50 nM. The cells were incubated at 
37 °C for 2 hours before the addition of 10% FBS with 100 U/ml penicillin and 100 μ g/ml streptomycin 
then cultured for a further 24 h for RT-PCR, tube-formation analysis. Experiments were repeated three 
times and results shown as the mean ± S.D (*p < 0.05).
RNA extraction and RT-PCR. Extraction of total RNA from BAEC was performed and complemen-
tary DNA (cDNA) was produced from total RNA extracts in two stages as described by the standard 
protocols and subsequently used to monitor bovine IRS1 mRNA expression. The gene-specific primer 
pairs used for PCR were optimized for cycle number (IRS1 = 35 cycles) and tm (58 °C). Primer pairs 
(Invitrogen) were selected by software Primer3 and the sequences are shown above. PCR products were 
analysed by 1.5% agarose gel electrophoresis. Ribosomal protein S14 expression was used as an internal 
standard.
Kinexus phospho-protein array analysis. BAEC or RCN were seeded in 6-well plates at a concen-
tration of 3 × 105 cells/2 ml in complete medium. After 48 h incubation, the medium was replaced with 
serum-free medium for a further 24 h incubation then 5 μ g/ml mCRP was added to the cells and allowed 
to incubate for 8 min at 37 °C. To screen the modulation of the signalling protein expression downstream 
of the mCRP receptor, a phospho-protein micro-array analysis of 500 phospho-site proteins, KinexTM 
Antibody Microarray (KAM)-1.2 was performed by Kinexus Bioinformatics (Vancouver, Canada). 
Proteins from mCRP-stimulated and un-stimulated cells were extracted according to Kinetworks instruc-
tions. Briefly, cells were washed twice with cold PBS. Protein was extracted using a buffer (pH 7.2) con-
taining 20 mM MOPS, 2 mM EGTA, 5 mM EDTA, 30 mM sodium fluoride, 60 mM β -glycerophosphate, 
20 mM sodium pyrophosphate, 1 mM sodium orthovanadate, 1 mM phenylmethylsulfonylfluoride, 3 mM 
benzamidine, 5 μ M pepstatin A, 10 μ M leupeptin, 1% Triton X-100 and 1 mM dithiothreitol on ice for 
cell lysis. Cell extracts were then collected and protein concentrations were measured by the Bradford 
protein assay using a plate reader and according to the manufacturer’s instructions (Bio-rad, Munchen, 
Germany). For each sample, protein (100 μ g in 50 μ l) was transferred to a fresh 1.5 ml Eppendorf screw 
cap and this was sent to Kinexus for analysis.
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Western blot Analysis. BAEC/RCN were seeded in complete medium in a 24-well plate at a cell 
concentration of 105/ml/well. After 48 h incubation, the medium was renewed with SPM and cells incu-
bated for a further 24 h Next, 5 μ g/ml mCRP was added and the cells incubated for 8 min at 37 °C. In 
addition, BAEC cultured under the same conditions were exposed to mCRP antibody (1 μ g/ml) imme-
diately prior to addition of mCRP in some experiments in order to identify any potential blocking effects 
on cell signalling. After rapid washing in cold PBS, cells were lysed with 120 μ l/well of ice-cold radio-
immunoprecipitation (RIPA) buffer (pH 7.5) containing 25 mM Tris-HCl, 150 mM NaCl, 0.5% sodium 
deoxycholate, 0.5% SDS, 1 mM EDTA, 1 mM sodium orthovanadate (EGTA), 1 mM phenylmethylsul-
fonyl fluoride (PMSF), 1% Triton X100 and 1 μ M leupeptin. The protein concentration of cell lysates 
was determined using the Bradford protein assay (Bio-rad, Munchen, Germany) and equal quantities of 
proteins (15 μ g) were mixed with 2 X Laemmli sample buffer, boiled in a water bath for 15 min then cen-
trifuged. Samples were separated along with pre-stained molecular weight markers (32,000–200,000 Da) 
by 12% SDS-PAGE. Proteins were electroblotted (Hoefer, Bucks, UK) onto nitrocellulose filters (1 h) 
and the filters were blocked for 1 h at room temperature in TBS-Tween (pH 7.4) containing 1% bovine 
serum albumin (BSA). Filters were stained with the following primary antibodies diluted in the blocking 
buffer, overnight at 4 °C on a rotating shaker: rabbit monoclonal antibodies to phospho-IRS1 (Y1179), 
rabbit polyclonal antibodies to γ -secretase subunit presenilin enhancer protein 2 (1:1000) from Acris 
Antibodies (San Diego, CA, USA), p-Tau (S404), NCAM, (1:1000), p-APP (Y757), PEN-2, p-ERK1/2 
and β -amyloid (1–42; Abcam, UK; in this case, cells were cultured with mCRP for 24 h) and mouse 
monoclonal antibodies to β -tubulin (1:1000) from Santa Cruz Biotechnology. After washing (5 × 10 min 
in TBS-Tween at room temperature), filters were stained with either goat anti-rabbit or rabbit anti-mouse 
horse-radish peroxidase-conjugated secondary antibodies diluted in TBS-Tween containing 5% de-fatted 
milk (1:1000, 1 h, room temperature) with continuous mixing. After a further five washes in TBS-Tween, 
proteins were visualized using ECL chemi-luminescent detection (Geneflow) and semi-quantitatively 
identified fold differences compared with house-keeping controls determined using Image-J software. All 
experiments were repeated at least twice and a representative example is shown.
NFT- Aggregation of Tau (human protein, Sigma). The aggregation of Tau244–372 (8 μ M) was 
induced by 150 μ M of arachidonic acid (Sigma) in buffer containing 10 mM Hepes (pH 7.6), 100 mM 
NaCl, 5 mM dithiothreitol for 24 h incubation at room temperature without stirring16. To detect a direct 
effect of mCRP on Tau aggregation, Tau was incubated with mCRP (10 μ g/ml) in the same buffer (minus 
arachidonic acid) for 24 h (4 h-5 days pilot study estimates were carried out to optimise this-data not 
included) at room temperature. The protein samples were fixed with 2% glutaraldehyde (Sigma), ultra-
centrifuged at 100,000 g for 30 minutes then spread on glass coverslips and allowed to dry in air. The 
samples were then sputter coated with gold and examined in a Jeol JSM-5600LV scanning electron 
microscope at an accelerating voltage of 12 kV and 10,000× magnification. Experiments were carried 
out at least twice and a representative example is shown.
Animals. Twenty four male 3xTg-AD mice and twenty four non-transgenic (NTg) mice were used 
in this study. The 3xTg-AD mouse model (primarily used here as a positive AD-like control) was 
genetically engineered at the University of California, Irvine to express the familial AD mutations 
PS1/M146V, APPswe and tauP301L17. The NTg mice had the same genetic background hybrid 129× 
C57BL6 as 3xTg-AD. Mice were bred from the Spanish colony established in the Medical Psychology 
Unit, Autonomous University of Barcelona18. Genotypes were confirmed by polymerase chain reaction 
(PCR) analysis of DNA obtained from ear punches. Animals were individually housed in Macrolon cages 
(Techniplast, Buguggiatta, Italy) with free access to food and water and maintained in a temperature 
controlled room (22 ± 2 °C) with 12 hours light/12 hours dark cycle. Animal handling, including surgical 
procedures, behavioral testing and necropsies, was performed at the facilities of the Animal Unit of the 
University of Barcelona, Spain.
The study was approved by the local animal experimentation ethics committee (Ref: DAAM-6991, 
CEEA, UB). All procedures were carried out in accordance with approved Spanish guidelines/legisla-
tion concerning the protection of animals used for experimental and other scientific purposes and the 
European Commission Council Directive 86/609/EEC on this subject. All experimental protocols were 
approved by the above authority.
Hippocampal injection of mCRP. mCRP, was delivered into the CA1 region of the mouse hip-
pocampus by stereotactic surgery procedures. Four-month old mice (n = 8 per group) were anesthe-
tized with 10 mg/kg xylacine (Rompun 2%, Bayer, Leverkusen, Germany) i.p. and 80 mg/kg ketamine 
(Ketolar 50 mg/ml, Pfizer, Alcobendas, Madrid, Spain) i.p. and placed in a stereotactic apparatus (David 
Kopf Instruments, Tujunga, CA). Bilateral infusions of either an experimental agent solution or artifi-
cial CSF (NaCl 148 mmol/l, KCl 3 mmol/l, CaCl2 1 mmol/l, MgCl2 0.8 mmol/l, Na2HPO4 0.8 mmol/l, 
NaH2PO4 0.2 mmol/l) were performed into the CA1 area of the hippocampus. Solutions of mCRP con-
tained a final content of 50 μ g. Injections were performed at a rate of 1 μ l/min at coordinates relative 
to Bregma of − 2.0 mm A/P, ± 1.2 mm M/L, − 1.5 mm V/D. One microliter of the testing solutions was 
delivered to the application point with a 25-gauge stainless steel cannula (Small Parts Inc., Miami, FL) 
connected to a Hamilton syringe through a Teflon tube. The syringe was attached to a micro-infusion 
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pump (Bioanalytical systems Inc., West Lafayette, IN). The cannula was left in position for 5 min after 
delivery to prevent the solution from surging back. One animal died immediately after surgery; other-
wise, eight mice formed the experimental groups.
Behavioral testing. Animals were tested for changes of non-cognitive and cognitive behavior at 
two-three weeks after hippocampal injections. A battery of tests was applied on fourteen daily consec-
utive sessions.
Sensorimotor responses: Visual reflex and posterior legs extension reflex were measured by holding 
the animal by its tail and slowly lowering it towards a black surface. Motor coordination and equilibrium 
were assessed by the distance covered and the latency to fall off a horizontal wooden rod and a metal 
wire rod, as described previously19. Prehensility and motor coordination were measured as the distance 
covered on the wire hang test, which consisted of allowing the animal to cling from the middle of a hori-
zontal wire (2 mm diameter × 40 cm length) with its forepaws for two trials of 5 s and a third 60 s trial.
Corner test: Neophobia to a new home-cage was assessed by introducing the animal into the center 
of a standard square cage (Macrolon, 35 × 35 × 25 cm) with fresh bedding and counting the number of 
corners visited and rearings during a period of 30 s. The latency of the first rearing was also recorded.
Open field test: Mice were placed in the center of the apparatus (home-made, wooden, white, 
55 × 55 × 25 cm high) and observed for 5 min. Patterns of horizontal locomotor activity (distance cov-
ered and thigmotaxis) and vertical movement (rearings) were analyzed throughout the test. Initial freez-
ing, self-grooming behavior and the number of urine spots and defecation boli were also recorded.
Dark and light box test: Anxiety-like behavior was measured in a dark-light box. The apparatus con-
sisted of two compartments (black: 27 × 18 × 27 cm with a red light; white: 27 × 27 × 27 cm with white 
lighting intensity of 600 lux) connected by an opening (7 × 7 cm). The mice were introduced into the 
black compartment and observed for 5 min. The latency to enter the lit compartment, the time spent in 
the lit compartment and the number of rearings were recorded.
Boissier’s four hole-board test: Exploratory behavior was measured as the number of head-dips and 
time spent head-dipping on each of the four holes (3 cm diameter) equally spaced in the floor of the 
hole-board (woodwork white box of 32 × 32 × 32 cm). The latencies of movement, first dipping and four 
hole dipping were recorded.
Tail suspension test: Mice were suspended by the tail to assess depression-like behavior. The mouse 
was hanged 30 cm above the surface. The tail was fixed with adhesive tape at 1 cm from its tip. The dura-
tion of immobility (defined as the absence of all movement except for those required for respiration) 
was scored during 6 min.
Object recognition test: Animals were placed in the middle of a black maze with two arms angled 
90°, each measuring 25 cm × 5 cm. The 20 cm high walls could be lifted off for easy cleaning. The light-
ing intensity was 30 lux. The objects to be discriminated were made of wood (5–6 cm high, brightly 
colored). After two previous days of habituation, the animals were submitted to a 10 min acquisition 
trial (first trial) during which the mouse was placed in the maze in the presence of two identical novel 
objects (A+ A’) placed at the end of each arm. A 10 min retention trial (second trial) occurred 2 h later, 
replacing object A’ in the maze by object B. Another 10 min retention trial (third trial) occurred 24 h 
later, replacing object A in the maze by object C. The time that the animal explored the new object and 
the old object were recorded. In order to avoid object preference biases, the sequence of presentation of 
the different objects was counter-balanced in each experimental group. The maze and the objects were 
cleaned with 96° ethanol between different animals, to eliminate olfactory cues.
Morris water maze test: Animals were tested for spatial learning and memory in the Morris water 
maze (MWM), consisting of one day of cue learning and six days of place task learning for spatial ref-
erence memory, followed by one probe trial. To test the spatial learning acquisition, mice were trained 
to locate a hidden platform, 10 cm in diameter, located 20 cm from the wall and 0.5 cm below the water 
surface. This was placed in a circular pool 100 cm in diameter, 40 cm height, with 25 °C opaque water, 
surrounded by black curtains. The animals learned to find the platform using distinctive landmarks as 
visual cues (four trial sessions of 60 s per day). For details of the procedure see: García-Mesa et al.19. 
On day seventh, after one trial of place learning, the platform was removed and the mice performed 
a probe trial of 60 s to test the retention of learning. A computerized tracking system (SMART, Panlab 
S.A., Barcelona, Spain) allowed to measure the distance covered during the learning tasks, along with the 
time spent in each quadrant of the pool after the removal of the platform in the probe test. For statistical 
analysis, 2-way ANOVA was used and significance was defined as *p < 0.05.
Histological analysis. After completion of the behavioral tests, at 1 month after injection, mice were 
anesthetized as described above and transcardially perfused with 100 mM phosphate buffer (PB, pH 
7.4) containing 0.1 mg/ml heparin (Mayne Pharma, Spain) followed by 4% paraformaldehyde in PB. 
Brains were removed and post-fixed overnight in cold paraformaldehyde, rinsed with cold PB and then 
dehydrated in a graded ethanol series, cleared in xylene and embedded in paraffin. Serial sections were 
cut throughout the brain at 5 μ , and IHC was carried out at 1 mm intervals throughout the brain-details 
described below in the section on immunohistochemistry (animals n = 5 per group) in order to deter-
mine expression and localization of mCRP, p-Tau, p-IRS-1 and Aβ .
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Anatomo-pathological study. Brain samples: 1) Ischaemic stroke with AD: Samples were obtained 
from the Institute of Neuropathology Brain Bank, University Hospital of Bellvitge, Catalonia and ethical 
approval for the work was granted. The tissue samples had been collected within 4 hours of death from 
the refrigerated bodies of 10 patients who died 2–53 days after stroke following middle cerebral artery 
occlusion (details are provided in Table 1). Patients presented with dementia, confirmed in memory clin-
ics and the diagnosis of probable AD was confirmed by anatomopathology. All the AD cases had a history 
of progressive dementia and were selected on the basis of a diagnosis according to CERAD of ‘definite 
AD’20 and a Braak tangle stage of V-VI21; according to NIA-Alzheimer’s Association guidelines22, AD 
neuropathological change was considered a sufficient explanation for the dementia in all cases. Samples 
were dissected into infarcted (identified with 2, 3, 5-triphenyltetrazolium chloride), peri-infarcted and 
normal looking unaffected tissue as previously described23. Peri-infarcted tissue showed structural integ-
rity but was characterised by oedema, altered morphology of the neurons (some showing changes of 
apoptosis), and angiogenesis. Tissue from the contralateral hemisphere served as a control. Samples were 
dissected into 2 mm diameter pieces and either frozen in liquid nitrogen at -70°or fixed in 10% buffered 
saline prior to paraffin embedding.
2) Alzheimer’s tissue (post mortem) from 20 patients and 10 negative controls was obtained from the 
Brain Bank in Bristol (UK). Tissue sections were obtained from blocks of the cerebral cortex, specifically, 
from the frontal lobe, parietal lobe and occipital lobe. Details are shown in Table 2. The AD cases all had 
a history of progressive dementia and were selected on the basis of a diagnosis according to CERAD of 
‘definite AD’20 and a Braak tangle stage of V-VI21; according to NIA-Alzheimer’s Association guidelines22, 
AD neuropathological change was considered a sufficient explanation for the dementia in all cases. The 
normal controls had no history of dementia, few or no neuritic plaques, and no other neuropathological 
abnormalities
Immunohistochemistry. Double immunofluorescence and/or immunohistochemistry were used 
to assess the distribution of mCRP (mouse anti-human mCRP-specific antibodies 8C10 and p-IRS-
1-Y1179) and activated microvessels (CD105/endoglin rabbit polyclonal antibody) as well as the presence 
of β -amyloid and p-tau (rabbit polyclonal antibodies). After incubation with primary antibodies for 1 h 
at room temperature (1:100), sections were washed and then incubated with the appropriate second-
ary antibodies (1:50) – peroxidase (HRP), fluorescein isothiocyanate-conjugated sheep anti-mouse IgG 
(Jackson) or tetramethylrhodamineisothiocyanate-conjugated rabbit anti-goat (Jackson). Images were 
captured with Nikon 80i Digital Microscope using Nis Elements 3.21 software with multichannel cap-
ture option. Negative control slides were included where the primary antibody was replaced with PBS. 
Vecor ABC kits were used for all IHC and the Vector mouse on mouse (M.O.M) was used when applying 
mouse primary CRP antibodies to the murine brain sections with mouse secondary.
Statistical analysis. All in vitro experiments were performed at least twice and where appropriate, 
SPSS package was used with a student t test and ANOVA to determine statistical differences from min-
imum of n = 3 groupings of test versus control. For the animal experiments, based on the advice of a 
medical statistician and the experience of behavioural studies of our team, n = 8 was used for each group 
of mice providing the minimum number to allow significant data to be recognized.
Ethics statement. The mice were bred from the Spanish colony established in the Medical Psychology 
Unit, Autonomous University of Barcelona18. Genotypes were confirmed by polymerase chain reaction 
(PCR) analysis of DNA obtained from ear punches. Animals were individually housed in Macrolon 
Patient 
Number IS/AD AGE SEX
Time of death 
alter IS GDS-Fast/CDR
Hachinski 
scale
Plaque 
expression 
of nCRP
Plaque 
Expression 
of mCRP
Microvessel 
Expression 
of nCRP
Microvessel 
Expression 
of mCRP
1 AD 84 M — 6A 1 — — + — —
2 AD 84 M — 7B 1 — + — + 
3 AD 77 M — 5 2 — — — —
4 AD 84 M — 7C 1 — + + — + —
5 AD 87 F — 6B 0 — + — — + 
6 AD/IS 63 F 2 4 9 — + + + — + + + 
7 AD/IS 51 M 3 3 8 — + + + + + + + 
8 AD/IS 51 M 9 3 10 — + + + + + 
9 AD/IS 68 M 19 5 8 — + + + — + + 
10 AD/IS 75 M 29 6D 11 — + — + + 
Table 1. Patient details of Ischaemic stroke samples +/− AD from Belvitge Hospital.
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cages (Techniplast, Buguggiatta, Italy) with free access to food and water and maintained in a temper-
ature controlled room (22 ± 2 °C) with 12 hours light/12 hours dark cycle. Animal handling, including 
surgical procedures, behavioral testing and necropsies, was performed at the facilities of the Animal 
Unit of the University of Barcelona, Spain. The study was approved by the local animal experimentation 
ethics committee (Ref: DAAM-6991, CEEA, UB). All procedures were carried out in accordance with 
approved Spanish guidelines/legislation concerning the protection of animals used for experimental and 
other scientific purposes and the European Commission Council Directive 86/609/EEC on this subject. 
All experimental protocols were approved by the above authority. Regarding the human study, the insti-
tutional review board and local ethical committee (CEIC) of the Hospital Universitari Mútua Terrassa 
provided clearance for the study. All patients signed informed consent.
Results
Kinexus quantitative phospho-protein screens demonstrated that mCRP increased phospho-
rylation of Tau and IRS-1 in BAEC. We performed a Western phospho-protein screen on BAEC 
exposed to mCRP (10 μ g/ml, 8 minutes; based on our previous published findings of maximal acute 
phosphorylation induced by mCRP). Results demonstrated that Tau was phosphorylated (S516) by 
BB NO MRC ID DIAG 1 DIAG 2 DIAG 3 AGE SEX
Braak 
Stage
PM 
DELAY APOE
119 BBN_8748 AD NO NO 91 F 6 78 3.4
217 BBN_8846 AD NO NO 84 F 6 96 4.4
221 BBN_8850 AD NO NO 84 F 5 41 4.4
270 BBN_8899 AD NO NO 92 M 5 45 2.4
317 BBN_8945 AD NO NO 91 F 4 12 4.4
341 BBN_8969 AD NO NO 95 M 3 48 3.3
434 BBN_9060 AD NO NO 87 M n/a 12 n/a
451 BBN_9076 AD NO NO 84 F 5 20 3.4
456 BBN_9081 AD Argyrophilic grain disease NO 92 M 2 84 n/a
465 BBN_9090 AD CAA NO 83 M 6 20 3.3
496 BBN_9120 AD NO NO 84 F n/a 24 2.3
530 BBN_9154 AD NO NO 81 M n/a 28 3.4
677 BBN_9255 AD NO NO 81 M n/a 16 n/a
691 BBN_9269 AD NO NO 83 M 4 99 3.4
697 BBN_9275 AD NO NO 87 M 6 36 4.4
731 BBN_9309 AD NO NO 88 F 4-5 88 3.3
745 BBN_9323 AD NO NO 84 F 6 20.5 2.3
760 BBN_9338 AD CAA SVD 95 M 4 27 3.4
768 BBN_9346 AD NO NO 88 F 6 64 3.3
821 BBN_4232 AD CVD NO 84 F 6 65.5 n/a
160 BBN_8789 CONTROL NO NO 78 F 2 24 n/a
323 BBN_8951 CONTROL NO NO 96 F n/a n/a n/a
721 BBN_9299 CONTROL NO NO 90 M 2 5.5 2.3
733 BBN_9311 CONTROL NO NO 93 M 3 37.75 2.3
751 BBN_9329 CONTROL NO NO 80 M 0 45.75 3.3
762 BBN_9340 CONTROL NO NO 94 F 2 21 2.3
781 BBN_4205 CONTROL NO NO 87 M 2 24 3.3
786 BBN_9354 CONTROL NO NO 85 M 2 30.5 3.3
818 BBN_4229 CONTROL NO NO 87 F 3 47 2.3
826 BBN_9365 CONTROL NO NO 86 F 2 32 3.4
Table 2.  AD patient/specimen details from Bristol Brain Bank, UK. The AD cases all had a history 
of progressive dementia and were selected on the basis of a diagnosis according to CERAD of ‘definite 
AD’53 and a Braak tangle stage of V-VI54; according to NIA-Alzheimer’s Association guidelines55, AD 
neuropathological change was considered a sufficient explanation for the dementia in all cases. The 
normal controls had no history of dementia, few or no neuritic plaques, and no other neuropathological 
abnormalities.
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mCRP (> 2 fold) and also IRS-1 (Y1179) (> 3 fold) amongst other proteins including focal adhesion 
kinase and Bcl2 (Fig.  1A). Western blotting confirmed the results of the kinexus screen showing that 
IRS-1 and tau were phosphorylated in the presence of mCRP in BAEC after 8 minutes. Approximately 
a 4.5 fold increase in p-IRS-1 was found in BAEC exposed to mCRP for 8 minutes (Fig. 1B), and p-tau 
increased by approximately 4.2 fold (Fig. 1C). The bar chart demonstrates the increase compared with 
control, untreated cells using β -tubulin as a house-keeping control. Since increased Tau phosphorylation, 
tangle formation and abnormal amyloid processing may be linked to vascular dysfunction in endothe-
lium24,25, we went on to examine if mCRP could affect/induce NFT formation, β -amyloid 1–42 cleav-
age or γ -secretase-presenilin expression in BAEC. The cleaved amyloid fragment (1–42) was increased 
Figure 1. Kinexus Western phospho-microarray analysis and Western blotting of mCRP-induced 
signalling in BAEC. A shows quantitative Kinexus phospho-protein screening array carried out on BAEC 
after exposure to mCRP (8 minutes) demonstrated up-regulation of several potentially important proteins 
that may be implicated in AD pathology including Tau (2.3 fold) Focal adhesion kinase and IRS-1 (3.4 
fold). IRS-1 was investigated in more detail in our in vitro studies Fig. 1B shows by Western blotting in the 
same samples, that mCRP induced approximately a fourfold increase in p-IRS expression compared with 
control untreated cells (bar chart). P-Tau was also increased by approximately 5-fold (C) and in addition, we 
showed that the cellular content of Aβ 1–42 increased 3-fold over 24 h whilst PEN-2 also increased (2-fold; 
8 minutes). These experiments were carried out at least twice and a representative example is shown.
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in samples (intracellular) treated with mCRP (5 μ g/ml/24 h) as shown by Western blotting (2.8 fold) 
(Fig.  1D). Extracellular levels of amyloid-β (1–42) were not significantly altered as measured in the 
medium (data not shown). γ -secretase active sub-unit (presenilin enhancer protein 2; PEN-2) and 
phosphorylated amyloid precursor protein (p-APP) expression was also increased around 2.5 fold after 
8 minutes treatment (Fig. 1D) indicating a potential mechanism for amyloid cleavage. mCRP also phos-
phorylated ERK and AKT as shown previously (data not included;13).
Down-regulation of IRS-1 with siRNA significantly inhibited the ability of mCRP to induce 
angiogenesis in BAEC. To confirm that IRS-1 was important in mediating the angiogenic properties 
of mCRP, we down-regulated IRS-1 (> 85%; Fig. 2A) using siRNA and this reduced the ability of mCRP 
to induce tube formation in a matrigel substrate by approximately 50% (Fig. 2B; *p < 0.05 and **p < 0.01). 
Thus mCRP appears to operate through a pathway involving IRS-1 in order to mediate its pro-angiogenic 
activities (see proposed signalling pathway; Supp. Fig. 3). Similarly, addition of our mCRP antibodies 
(1 μ g/ml) prior to addition of mCRP inhibited signalling through MAP kinase (ERK1/2 and IRS-1) and 
also perturbed angiogenesis following analysis of mCRP-induced tube-like structure formation, whilst 
the control IgG antibody had no effect (data not included) (Fig. 2C,D respectively). Note nCRP was not 
tested in these assays as we have previously shown that it has no pro-angiogenic activity8.
mCRP induced increased vascular permeability with instability of cell-cell junctions and 
haemorrhagic angiogenesis in vivo. Electron microscope images of tube-like-structures produced 
in matrigel from a spheroid assay, in the presence of mCRP (10 μ g/ml; 24 h) showed increased gaps 
between adjacent cells suggesting a possible increase in vascular permeability (Fig.  3A). In addition, 
sprouts formed in the presence of mCRP were longer and thinner than those cultured in complete 
medium (detailed data published elsewhere). Changes to the structure and/or organisation of the blood 
vessels was confirmed in vivo, with mCRP (10 μ g/ml applied to dorsal matrigel implants, inducing 
haemorrhage after 72 h, unlike the normal pro-vascularization seen in the presence of VEGF (25 ng/ml). 
Although we have thoroughly tested native CRP previously and found no angiogenic response in vitro, 
we included it as a testing molecule for confirmation in vivo. Native CRP produced no notable angiogenic 
response (n = 3 and statistical comparison was not carried out with these implants) (Fig. 3B). In addition, 
using a Millipore cell permeability assay, we showed that incubation of a BAEC monolayer cultured on 
collagen with 10 μ g/ml mCRP (8 h) induced a significant increase in cell permeability (p < 0.01), and 
similar to that produced by pre-incubation with 10% DMSO (Fig. 3C).
mCRP increased the expression of N-cadherin-often associated with inflammatory/unstable or aggres-
sive angiogenesis (Fig. 3D); but no other cell surface markers of EC activation/cell junction remodelling 
(ICAM-1, VCAM, α 5β 3 integrin-data not included).
In vivo mouse study. Treatment with mCRP significantly deteriorated non-cognitive and cognitive 
behavior of none-transgenic mice. Intrahippocampal injection of CRP distinctly deteriorated several 
aspects of general behavior and cognitive responses tested in NTg mice. As positive controls, five-month 
old 3xTg-AD mice showed changes to their behavior and their capacity of learning and memory, as 
expected26,27.
mCRP did not decrease mouse reflex responses or coarse motor coordination on a rod, neither grip 
strength when clung on a wire (not shown). However, CRP reduced fine coordination significantly in 
NTg mice and as a trend in 3xTg mice, as shown in the wire hang test (Fig. 4A; p < 0.05). No signifi-
cant changes were induced by CRP treatment on the freezing time, horizontal and vertical movements 
and emotionality behavior as tested in the open field test (not shown). CRP did not induce neophobia, 
anxiety or depression-like behavior in the NTg mice as tested in the corner test, dark and light box test 
and tail suspension test, respectively, nor increased the level of these behaviors in Tg mice (not shown). 
However, the treatment with CRP induced a significant effect in the animal behavior in the Boissier’s 
hole board test, significantly decreasing the exploratory activity of NTg mice and further decreasing that 
of Tg mice (Fig. 4B,C; p < 0.05).
mCRP induced cognitive loss in NTg mice, but cognition-related effects could not be detected in 
Tg mice because of their own low capacity of learning and memory. Lack of visual discrimination of a 
previously explored object induced by mCRP treated mice was detected in the novel object recognition 
test when object A was replaced by object B and C (Fig. 5A–C; p < 0.05). Significant reduced acquisition 
of spatial learning and lack of retention of memory induced by mCRP were demonstrated in the MWM 
(Fig. 5D–F; p < 0.05).
Histology. Following injection at CA1 hippocampal region, mCRP staining was identified along the 
retrosplenial ventral tract, lining of the dorsal 3rd ventrical and within some surrounding major blood 
vessels and local cortical neurons (Fig.  6Ai) (n = 5) animals examined by histology in each group. All 
animals demonstrated the following similar features. Small microvessels were mCRP positive at the 
vicinity of injection site together with patchy areas of surrounding cortical neurons, especially in tem-
poral association areas and primary auditory area, layer 5 and 6a. Scattered groups of neurons were 
mCRP-positive within cortex regions adjacent to injection site (Fig. 6Ai–iii arrows), and in more distant 
cortical areas (primary and secondary motor areas, layers 2–5; Fig.  6Aiv). There was a homogenous 
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peri-nuclear staining in groups of neurons from the ipsilateral hippocampal region and cells appeared 
irregular and hypertrophic. The latter staining was more evident within hippocampal field CA1 pyram-
idal layer, dentate gyrus molecular and granular layers, but not in field CA3 (Figure Av) Interestingly, 
Figure 2. Effects of siRNA knock-down of IRS-1 on BAEC angiogenesis and cell signalling: BAEC were 
subjected to siRNA knock-down of IRS-1as described in the Materials and Methods section of this article. 
After 48 h treatment, approximately an 85% reduction in IRS-1 gene expression was noted (A). In contrast, 
NC siRNA had no effect on IRS-1 gene expression. Knock-down was tested for each experiment and found 
to be similar and the figure shows a representative example. (B) a reduction (50%) in mCRP-induced tube-
like-structure formation was seen in siRNA-treated cells. The bar chart shows significant reduction in tube 
formation in the presence of IRS-1 siRNA (**p < 0.01; *p < 0.05). Pre-incubation with our characterised 
antibody specific for mCRP (4 h; 1 μ g/ml) was able to inhibit both p-ERK1/2 and p-IRS-1 expression in 
BAEC (C) and also, significantly, tube-like-structure formation (D; *p < 0.05). Note nCRP was not tested 
in these assays as we have previously shown that it has no pro-angiogenic activity8 These experiments were 
carried out three times and where statistical analysis was performed, results represent the mean ± S.D of 
these experiments.
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there was also notable mCRP staining within hypothalamic neurons, posterior hypothalamic nucleus, 
lateral hypothalamic area and periventricular hypothalamic nucleus (Fig. 6Avi).
Figure 3. Characterization of mCRP-induced vascular activation: (A) BAEC spheroids were generated to 
examine the effect of mCRP on sprout structure and formation in a 3-dimensional system. In normal culture 
conditions, sprouting was slower, sprouts had a thicker appearance and cell-cell junctions were maintained 
(left panel). In the presence of mCRP, sprouts formed more quickly, were notably thinner in appearance 
and the inter-cellular gaps between cells was notably larger (right panel). (B) Dorsal matrigel implants 
containing mCRP (10 μ g/ml; 72 h) produced strong and visible haemorrhagic angiogenesis (iv; arrows) 
compared with a typical, normal looking vascular response seen in the presence of VEGF (ii; 25 ng/ml), 
whilst nCRP (10 μ g/ml) produced very little angiogenic response (p < 0.05 increase in the presence of mCRP 
and VEGF compared with control implants) (iii). In (C) the graph shows a significant increase in monolayer 
permeability in the presence of mCRP (10 μ g/ml; 8 h) using a Millipore-based filter assay, similar to that 
produced by 10% DMSO (p < 0.01 increase in FITC dextran penetrating the monolayer in the presence 
of either mCRP or the positive control DMSO), and lighter regions in the images shown indicate areas of 
increased permeability. (D) Expression of adhesion molecules was examined in BAEC treated with mCRP 
(10 μ g/ml; 24 h). NCAM expression was increased by approximately 2.8 fold whilst VCAM, ICAM and 
integrins were not affected (data not shown). β -tubulin was used as the house keeping control (gel and bar 
chart shown). These experiments were repeated at least twice and a representative example is shown.
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Mouse cerebrum microvessels close to hippocampal formation were strongly positive for mCRP. 
Microvessels from local cortex regions were also positively stained (Fig.  6Avii-viii) Distally, staining 
within microvessels was evident within the hypophysis region. Non-injected control animals showed no 
positive staining for mCRP in hippocampal or cortical regions (ix and x respectively).
In order to assess AD pathology, we performed p-Tau and Aβ immunostaining on serial sections 
of mice brains. CA1 pyramidal neurons and dentate gyrus molecular and granular layers were posi-
tively stained for p-Tau and Aβ (Figs 6Bii,iii and 6Ciii respectively). There was significant p-Tau staining 
within the hippocampal CA3 region, shown positive for mCRP (Fig. 6Biv-vi), whilst Aβ was primarily 
increased in sporadic cortical neurons and diffuse plaque-like elements associated with dying neurons 
(Fig. 6Cii,iii), mimicking the pattern seen in 3xTg mice (Fig. 6Civ,v). P-Tau staining was generally more 
abundant within cortical areas, mainly in big pyramidal neurons both in ipsilateral and contralateral 
hemisphere, with notable axonal positivity. This was especially evident with ecthorinal area 5, layer 5 
Figure 4. Behavioural changes observed following mouse-hippocampal injection of mCRP. Stereotactic 
injection of mCRP (50 μ g) directly into the CA1 hippocampal region of mice were examined 3–4 weeks after 
operation. A significant reduction in balance and grip was see in non-transgenic animals in the presence 
of mCRP (wire hang test; (A) whilst head dipping latency in the Boissier’s hole-board test was significantly 
increased in 3xTg mice and further increased when mCRP was present (B). In the same test, the latency 
to entry into 4 holes was significantly increased in both mCRP-treated non-transgenic and 3xTg mice. 
Statistical analysis was done using two-way ANOVA (*P < 0.05).
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and temporal association areas, layer 6. Peri-nuclear and axonal staining was seen in piriform cortical 
neurons of coronal (Bregma − 1.94 mm) sections in the hemisphere of injection. The later neurons were 
oedematous with ballooned, vacuolized morphology. Within ipsilateral basal ganglia, there were positive 
p-Tau neurons in thalamus, mainly posterior complex and posterior lateral nucleus of thalamus.
Since we identified an increase in p-IRS-1 within vascular endothelial cells on exposure to mCRP, 
we examined its expression and localization within our mCRP-treated animals by IHC. We identified 
increased p-IRS-1 expression within cortical neurons in the same areas of serial sections as mCRP-positive 
cells (Fig.  6Di,ii), as well as ventricular tracts (Fig.  6Diii,iv), hippocampal neurons (Fig.  6Dv,vi), some 
cortical microvessels and cortical plaques (Fig.  6Dvii,viii). No obvious staining was seen in cortical 
microvessels. Non-transgenic animals showed very little staining for p-IRS-1 (Fig. 6Dix).
Double IF labelling demonstrated co-immunolocalization of hippocampal neurons and CA1 and den-
tate gyrus neurons with mCRP (TRITC) and p-Tau (FITC) (Fig.  6Ei,ii respectively) as well as cortical 
microvessels mCRP (TRITC) and CD31 (FITC) (Figure 6Eiii).
Interestingly, serial sections from the same areas showed numerous mCRP positive medium sized 
microvessels that were also CD105-positive (Fig. 6Eiv,v). This was not seen in the contralateral hemisphere. 
Figure 5. Cognitive effects of mCRP on mice following hippocampal injection. (A–C) shows results for 
novel object recognition. Whilst no effects were seen at time zero, a trend was seen after 2 h and after 24 h, 
visual discrimination ratio was significantly decreased in the presence of mCRP in both non-transgenic and 
3xTg mice (C). Similarly, in the water maze test (D–F), mCRP-treated mice showed a significant increase in 
distance covered (D) and also reduction of % time in the target quadrant (E,F). Statistical analysis was done 
using two-way ANOVA (*P < 0.05).
www.nature.com/scientificreports/
1 4Scientific RepoRts | 5:13281 | DOi: 10.1038/srep13281
Figure 6. IHC of mouse brain tissue sections following mCRP hippocampal injection. Example staining 
results from histological and ICH analysis of mouse brain tissue sections (5 μ ). (A) (i–iii), shows mCRP-
positive ventricles (i), neurons close to the injection site (ii) and positive neuronal staining around cortical 
ventricular tracts (iii). (iv) There are numerous positively (peri-nuclear) stained irregular hypertrophic 
looking cortical neurons. In v, CA1 hippocampal neurons show strong mCRP-positivity whilst in vi, distant 
staining was observed in neurons of the hypothalamic region. In vii-viii, cortical microvessels are clearly 
stained for mCRP. ix shows non-transgenic control brain hippocampal neurons negative for mCRP staining 
and (x) shows cortical neurons also negatively stained for mCRP. (B) P-Tau positivity was increased in 
sections of cortical neurons. (i) shows an example of negative staining in hippocampal neurons of a control 
mouse whilst (ii) shows p-tau staining in cortical neurons from a 3xTg mouse and (iii) an equivalent section 
from an mCRP-injected animal. (iv) shows notable hippocampal (peri-nuclear) staining whilst (v) shows 
positive axonal cortical neuronal staining (v). Aβ staining is shown in (C) (i) shows negative staining in a 
normal non-injected mouse, ii and iii show plaque –like element staining and neuronal axons with peri-
nuclear staining respectively, whilst iv and v show sections of 3xTg mice demonstrating a similar staining 
pattern. (D) shows p-IRS-1 and mCRP staining in cortical neurons and plaques (i-ii; serial sections) and 
matching areas of serial sections showing co-localization in ventricular tracts local to the injection site 
(iii-iv), CA1 hippocampal neurons (v-vi). vii-viii, shows the presence of p-IRS-1-labelled plaque-like mCRP-
positive structures in the same region as mCRP positive areas. (ix) shows non-transgenic mouse cortical 
region negatively stained for p-IRS-1. (E) shows double immunofluorescent micrographs demonstrating Ca1 
neuronal co-localization of mCRP (TRITC) and p-Tau (i-iii; plus insert), and in cortical microvessels (iv; 
CD31 = FITC). Areas of direct co-localization appeared yellow. Due to antibody binding restrictions, active 
angiogenic vessels were labelled with CD105 in serial sections and compared with mCRP staining. V-vi 
show mCRP and CD105 staining in the same vessels of serial sections respectively. No positively stained 
microvessels were observed in the normal non-transgenic mouse cortex (data not shown). Magnification 
bars 2.5 mm = × 400).
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Deep into the brain within periventricular areas of thalamus, including paraventricular nucleus of thal-
amus, lateral habenula, intermediodorsal nucleus and central medial nucleus of thalamus had medium 
sized microvessels that were CD105 positive. The density of the above positive blood vessels was higher 
closer to hippocampal dentate gyrus with postive neurons for mCRP and p-Tau on serial sections.
Analysis of negative control sections (normal wild-type mice injected with buffer only) showed 
very little staining of neurons for p-Tau or Aβ and no evidence of Aβ plaques as shown in the various 
images, whilst in contrast, positive control 3xT mice showed similar staining pattern to non-transgenic 
mCRP-injected animals but more widespread and more cortical diffuse staining with the appearance of 
amyloid plaques (See Fig. 6A–E control images).
mCRP directly induced phosphorylation of potentially neurodegenerative signalling inter-
mediates in cortical neurons. Western blotting demonstrated that rat cortical neurons cultured in 
basal medium for 24 h prior to experimentation, exhibited a notable increase in expression of p-Tau and 
p-ERK1/2 following 8 minutes of exposure to mCRP (10 μ g/ml; Fig. 7i). In addition, p-IRS-1, p-AKT and 
p-APP were also increased in mCRP-treated cells (Fig. 7ii). Pre-treatment with blocking mCRP-antibody 
as described above before addition of mCRP notably reduced the phosphorylation of both p-ERK1/2 
and p-Tau (Fig. 7iii). In order to gain a further understanding of possible signalling pathways activated 
by mCRP in neurons, we conducted a KINEXUS Western phospho-protein array and results from this 
indicated a possible increase in expression p-FAK, p38 and p53 whilst a reduction in expression of RSK-1 
and ERK-5 was seen (Fig. 7iv). Further studies are required in order to identify the importance of these 
proteins in neuronal mCRP-induced signalling.
The aggregation of Tau244–372 was induced directly by addition of mCRP in vitro. When 
Tau was incubated with mCRP (10 μ g/ml) over a period of 24 h (time of incubation optimised from tests 
at 1 h-5 days in pilot studies not included) using a previously published protocol28, Scanning electron 
Figure 7. Western blotting showing mCRP-neuronal protein phosphorylation. Rat cortical neurons 
cultured in basal medium showed approximately an 8.5 fold increase in p-Tau expression and a 5-fold 
increase in p-ERK1/2 by Western blotting after 8 minutes treatment with mCRP (I-ii respectively; 10 μ g/
ml). In addition, (ii) mCRP induced increased phosphorylation of p-IRS-1 (5 fold), p-Akt (2.5 fold) and 
p-APP (2 fold). (iii) shows that pre-incubation with our anti-mCRP blocking antibody was able to inhibit 
mCRP signalling through p-ERK1/2 and p-Tau. These experiments were carried out at least twice and 
a representative example is shown. (iv) Kinexus phospho-protein Western array carried out on control 
neurons versus mCRP-treated cells (8 minutes; 10 μ g/ml) revealed further proteins that could be involved in 
neuronal-mCRP signalling including focal adhesion kinase (2.2 fold increase) and p-53 (1.7 fold increase). 
Magnification bars 2.5 mm = ×400).
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microscopical analysis of sputter-coated air-dried samples revealed increased helical tau filament polym-
erisation (dimerization) and formation to around 100 nm, whilst incubation with Arachidonic acid 
(150 μ M), used as a positive control produced a similar effect (Fig. 8).
Figure 8. Tau fibrilization assay. In vitro assay showing Tau 244–372 aggregation induced by mCRP (10 μ g/
ml; 24 h) (c), with a similar profile to that produced by the positive control arachidonic acid (150 μ M).  
(a) shows the control Tau incubated with all other buffer component’s minus CRP or arachidonic acid (b). 
These experiments were carried out at least twice and a representative example is shown. Magnification 
bars10 mm = 1 μ M.
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Anatomopathological study. Localization and expression of mCRP in Alzheimer’s brain tissue with 
and without ischaemic stroke: Native CRP was almost un-detectable in any of our brain tissue samples 
(AD/AD with or without IS; data not included; see reference29 Slevin et al. 2010 for information on 
stroke patients).
There was strong expression of mCRP in the stroke brains from patients with clinically confirmed 
dementia and neuropathology of AD (β -amyloid-positive plaques and, tauopathy). mCRP was observed 
in peri-infarcted and infarcted regions in plaques from all five stroke patients with AD and IS (Supp. Fig. 
1A; Table 1). mCRP positive neurons were also present in regions adjacent to the infarct but further away 
where the tissue appeared normal (i.e. no stroke tissue damage but positive for plaques and other features 
of neurodegeneration), the mCRP staining virtually disappeared. There was a weaker staining pattern 
within the infarcted core and particularly in old infarcts (14 days and beyond). Penumbral regions and 
other areas with strong tau/phospho-tau pathology showed the most intense staining for mCRP. The 
mCRP which as we demonstrated previously (8) becomes strongly expressed in ischaemic microvessels 
(Supp. Fig. 1B;), was also associated with neurons from within the plaques (Supp. Figure 1Bii) as well as 
with plaque elements with the appearance of neurofibrillary tangles (Supp. Fig. 1C). Interestingly, in AD 
patients (without known stroke), we observed frequent regions of tissue damage with the appearance of 
small cortical lacunes, and these regions stained most strongly for mCRP. mCRP-positive areas clearly 
surrounded neuronal plaques, but the staining was negative in end-stage dead neurons.
In sections from patients with clear AD pathology but no evidence of tissue damage caused from lacu-
nar stroke or other hypoxic conditions, there was some staining of mCRP in neuronal plaques however 
there was no microvessel mCRP localization, suggesting further, that, mCRP deposition in neurons and 
microvessels are independent. The presence of mCRP in plaques maybe related to mCRP involvement 
with AD pathophysoiology and denovo synthesis and not only due to deposition from leaky microvessels 
in tissue infarcted areas.
Observation of microvessels from within the infarcted and peri-infarcted regions also showed an 
intense staining of mCRP (FITC green) in β -amyloid-positive (Rhodamine-red) capillaries (Supp. Fig. 
1D; Table 1). Arrows show areas of co-localization in confocal images. The increased microvessel mCRP 
staining was present also in vessels without amyloid, but staining was more prominent in sections with 
severe amyloid angiopathy. Vessels expressing mCRP were almost always CD105-positive suggesting acti-
vation and perhaps the potential to undergo angiogenesis (IHC staining with anti-CD105-DAB brown 
and IF TRITC red using anti-mCRP antibodies; Supp. Fig. 1E). No expression of mCRP was seen in the 
contralateral hemispheres of patients following ischaemic stroke (data not included). Supp. Figure 2i 
shows similarity between mCRP staining of cortical neurons and in a serial section, tau phosphorylation 
of the same region in stroke-affected cerebral cortex. In Supp. Figure 2ii, lacunar stroke micro-infarct 
core has been identified (arrow) and a gradual reduction in intensity of mCRP staining is seen as we 
move away from the damaged tissue region. This was common to all similar regions we examined.
Supp. Figure 3 shows a novel signalling pathway through which mCRP may contribute to pathological 
development of dementia. Key novel elements include IRS-1, and NCAM.
Discussion
Epidemiological studies have demonstrated that approximately 25% of elderly patients show signs of 
dementia within 3 months of ischaemic stroke. Desmond et al.1 demonstrated a significant increased 
risk of dementia associated with ischaemic stroke with specific relationships to cerebral hypoxia/ischae-
mia. As mentioned earlier, ischaemic stroke exacerbates dementia in Alzheimer´s patients and animal 
models have demonstrated a strong relationship between neuroinflammation, increased platelet activa-
tion (which could involve mCRP30—; and AD/stroke toxicity4,31. In these cases, hypoxia is often associ-
ated with small vessel disease and vessel constriction or in-patency (vascular dementia; CAA). Vascular 
remodelling is a key feature of the neurodegenerative process, abnormal angiogenesis being strongly 
associated with β -amyloid deposition and the presence of NFTs in a study of post-mortem brain samples 
from AD patients, suggesting a relationship with tissue injury32. Similarly, Meyer EP et al.33 showed using 
APP23tg mice and vascular casting, that vasculature often ended (was blocked) at the sites of developed 
amyloid plaques and surrounding hypoxic regions had tried to compensate by eliciting angiogenesis.
Since circulating native CRP levels increase dramatically during cardio/cerebrovascular events and 
mCRP is now known to become tissue and cell associated as a monomer with strong biological prop-
erties7,10,30,34, it made sense to investigate if it could be involved in modulating cell signalling associated 
with plaque development or vascular damage associated with small vessel disease in AD affected indi-
viduals. In this regard, we can only measure circulating pCRP concentrations (as pCRP is not found 
associated with tissue/cells), which as stated previously range during active infection and prior to/during 
cardio/cerebro-vascular ischaemia between 40–200 μ g/ml in patients7. And hence our chosen mCRP 
delivery of between 5–10 μ g/ml (in vitro) and-50 μ g/total drip- (1 μ g/minute) delivery comfortably fits 
within these limits and was designed to reflect this following our previous work and that of others show-
ing no cytotoxicity to cells within this range of use8–10.
In addition, our previous histological studies of ischaemic stroke patients allowed us to identify the 
expression of mCRP in co-existing amyloid plaques and elements with the appearance of NFTs; however, 
where there was no evidence of previous ischaemic stroke or in regions of lacunar/silent strokes, very 
little mCRP was seen. In patients with AD but without evidence of stroke, mCRP was only evident by 
www.nature.com/scientificreports/
1 8Scientific RepoRts | 5:13281 | DOi: 10.1038/srep13281
its relatively weak incorporation into some AD plaques neighbouring damaged neurons, suggesting an 
additional possible de novo mechanism of synthesis distinct from deposition through vascular leakage. 
Native CRP was not found to be expressed in any of the tissue samples8.
Here, we demonstrate a potentially key role for mCRP in patients with previous vascular or ischaemic 
brain damage (which could include brain trauma injury) in perpetuating dementia onset. Our four key 
elements for proof of principle are 1) mCRP induces abnormal angiogenesis, producing vessels in vitro 
allowing, greater permeability, and signalling activation reflecting a possible mechanism for perpetuating 
inflammation; 2) CA1 hippocampal injection of mCRP in a murine model of AD, directly induced cog-
nitive and behavioural decline concomitant with AD-like brain structural changes including increased 
expression of p-Tau and β -amyloid plaque production; 3) mCRP induced tau filament polymerization 
in vitro and in addition, mCRP induced neuronal signalling pathways associated with AD pathological 
development; 4) a detailed histological study in patients with AD with and without stroke demonstrated 
a strong expression and co-localization of mCRP and associated signalling molecules with AD elements, 
with strong co-localization to areas of tissue disruption caused by infarct.
In evidence for the impact of mCRP on vascular function, we showed using tri-dimensional spheroids 
in combination with TEM that inter-cellular spaces or gap junctions between adjoining cells were notably 
greater in sprouts developing from mCRP-treated tri-dimensional spheroids. In addition, mCRP signif-
icantly increased the permeability of a confluent, barrier endothelial cell monolayer to FITC dextran 
and also produced haemorrhagic tissue lesions concomitant with angiogenesis following dorsal matrigel 
implantation in vivo (examined macroscopically only). This data suggests strongly that mCRP may induce 
an increased permeability of abnormally developing microvessels after tissue injury, and this could be 
linked to exacerbated inflammation and/or haemorrhage in the region if the same pattern were repro-
duced in vivo in developing or damaged microvessels. This could have relevance to vascular dementia 
and that linked to ischaemic stroke, where, the micro-environment existing in the vicinity of susceptible 
vessels may be unbalanced in the presence of mCRP leading to more aggressive but less efficient angio-
genesis producing the same immature and weak vessel walls seen in tumour/plaque vascularisation33,35,36.
We then investigated the potential signalling mechanisms through which mCRP might affect vascular 
formation and development using a specifically designed Western phospho-protein screening array with a 
particular focus on vascular activation pathways associated with neurodegenerative disease. Quantitative 
analysis of protein phosphorylation changes induced in BAEC in the presence of mCRP demonstrated 
that p-IRS-1 and p-tau amongst others were notably increased. Insulin growth factor and its substrates 
IRS-1/2 have been implicated in the vascular complications of diabetes associated with AD in association 
with β -amyloid clearance; however the exact role and mechanism are not yet understood37. Here, we 
show that siRNA knock-down of IRS-1 partially inhibited the pro-angiogenic effects of mCRP by block-
ing tube-like structure formation in matrigel and abnormal, fragile sprout formation in EC-generated 
spheroids. IRS-1 is now known to be strongly pro-angiogenic, and down-regulation of its expression 
blocks angiogenesis both in vitro and in vivo38. Hence, this is one potential novel mechanism that mCRP 
may try to promote new vascular growth in angiogenic areas of damaged or stroke-affected areas of AD 
brain tissue39. It is interesting to consider that the insulin-like growth factor-1 receptor (IGF-1R) might 
be a candidate receptor for mCRP binding since it directly phosphorylates IRS-1 and its inhibition has 
also been shown to be sufficient to block angiogenesis.
We also noted that mCRP had the ability to phosphorylate tau on serine 214. Recently, Zhu et al.29 
demonstrated that in vascular ECs, phosphorylation of non-neuronal tau at serine 214 was associated 
with abnormal microtubule organization. They further described how this activated form of tau induced 
intracellular gaps and increased macromolecular permeability in a PKA/cAMP dependent mechanism 
ultimately disrupting the EC barrier. In addition, Balczon, et al.40 showed that pseudomonas aeroginosa 
exotoxin Y was able to hyper-phosphorylate tau in pulmonary microvascular ECs and that this disrupted 
microtubule assembly, potentially leading to increases vascular permeability, and barrier breakdown/
oedema in vivo. In addition, we showed that mCRP induced an increase in expression of NCAM-a 
marker of immature endothelial cells and linked to active increased EC permeability41, but did not affect 
VCAM. ICAM or integrin expression. Therefore, Tau phosphorylation/NCAM activation could be a 
mechanism through which mCRP increased the EC permeability. Note, our previous work and others 
clearly demonstrated an almost complete lack of biological signalling activity relating to angiogenesis 
and inflammation of pCRP8,30.
Since mCRP was able to phosphorylate tau, we examined other pertinent candidates linked to neu-
rodegenerative progression and identified increased expression of both amyloid 1–42 (24 h) and p-PEN-
2/p-APP within 8 minutes of treatment. This is not the first report of β -amyloid-cleavage in EC. This 
phenomenon has been reported recently by Rajadas et al.42 in Hep-1 cells associated with enhanced 
APP expression and linked to endothelial and vascular abnormality34. Therefore, de novo modification/
production of toxic amyloid could also be related to mCRP-induced endothelial dysfunction in vitro, in 
vivo, and potentially in vascular-based dementia. We investigated if the antibody to mCRP could poten-
tially block the down-stream signalling activation and found that pre-incubation with anti-mCRP did 
significantly reduce angiogenesis and also signalling through p-ERK1/2 and p-IRS-1 with an ND50 value 
of around 1 μ g/ml (not kinetically determined).
Further evidence of a possible role of mCRP in AD has been provided by Strang et al.11 who recently 
showed that Aβ plaques generated in vitro were able to dissociate native CRP to mCRP. In addition, 
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cortical plaques from patients with AD were positive for mCRP whilst nCRP was not present, suggesting 
a strong link to AD pathology and that mCRP could be a driving feature of plaque development.
Bi et al.43 suggested that intra-vascular pCRP injection in mice resulted in increased expression of 
APP and presenilins. However, they were not able to determine the fate of CRP, its possible conversion 
to the monomeric form, nor activation of these proteins. In addition the use of the murine model which 
does not respond to inflammatory stimulus by increasing CRP is an unusual model to apply to this 
protein, and hence this work, although mentioned in passing, may not provide any significant advances 
to our knowledge.
Investigating this possibility further, we showed that direct hippocampal injection of mCRP in mice 
resulted in both CA1-3 positively stained neurons as well as local microvascular staining. Neuronal cells 
stained concomitantly with p-Tau and cortical regions of microvessels positive for mCRP were also 
CD105 and p-IRS-1-positive (serial section analysis) suggesting a promotion of angiogenesis or vascular 
activation. mCRP became ‘stuck’ indefinitely in the ECM and was found in cortical, hippocampal and 
hypothalamic neurons, producing vacuolated and/or swollen cells (present and remaining more than 
1-month after injection). No overall cell loss was observed, and control mice injected with equivalent 
concentrations of CSF protein showed no reaction nor signalling activation. Tau aggregates were seen 
localised to abnormal looking neurons and axons also became p-Tau-positive. In addition, β -amyloid-like 
plaques were present and positively stained for mCRP, and overall the pattern of pathological staining 
was not dissimilar to that produced in transgenic animals visualised by IHC/histology. Most importantly, 
animals showed behavioural and cognitive deficits similar to triple transgenic animals with induced pro-
gressive AD-like brain pathology, including novel object recognition failure, Morris water maze distance 
and time, and wire-hang testing44. This provides the first indirect evidence that mCRP laid down within 
the brain parenchyma (such as following brain infarction) might directly promote development of neu-
rodegeneration. No further cognitive or behavioural decline was observed in 3xTg animals that were also 
injected with mCRP. Since the level of decline in these animals is quite severe (and significantly more 
than that seen in mCRP-injected only animals) this was perhaps to be expected. In addition, mCRP was 
not detected in normal nor 3x Tg mice even as a consequence of or concomitant with neurodegenerative 
pathway activation, suggesting it is not produced and/or deposited in this model as part of a normal 
inflammatory cascade, nor produced by de novo synthesis within the brain.
Since mCRP was found within neurons, we examined the effects of this molecule on cortical neuronal 
signalling using Western blotting and Kinexus phospho-microarrays. Similar to ECs, mCRP induced an 
increase in p-ERK1/2 and p-Tau expression, and in addition, p-APP, p-Akt and p-IRS-1 were stimulated 
within 8 minutes exposure. Once again, blocking mCRP-antibody incubation was sufficient to inhibit 
p-ERK1/2 and p-Tau signalling. Additional proteins increased on the microarray included focal adhesion 
kinase (FAK) and p53, both of which could influence signalling linked to Aβ -induced cellular apop-
tosis, although further characterization of their importance would need to be carried out45. Similarly, 
Aβ -induced JNK-IRS-1 signalling is also implicated in insulin resistance in diabetes and to pathological 
progression of AD46.
One of the hallmarks of AD is the fibrillization of tau protein wherein, individual monomers aggre-
gate, particularly when hyper-phosphorylated eventually to form paired helical filaments47 and this can 
be visualised using S.E.M./T.E.M48. In our study, we showed that tau oligomers produced evidence of tau 
filament assembly/aggregation in the presence of mCRP, and similar to that induced by arachidonic acid 
used as a positive control. We also identified similar looking mCRP-positive staining fibrils within our 
murine-mCRP-injected brainsa and AD patients with stroke. Several studies have identified a correlation 
between neurotoxicity and cognitive dysfunction, tau aggregate expression preceding NFT formation in 
animal models49, which leads to a potential hypothesis that mCRP could contribute to this pathological 
progression.
Interestingly, Thiele et al.50 recently showed that native CRP dissociating to mCRP in a rat intravital 
model of lipopolysaccharide-induced cremasteric muscle inflammation, significantly enhanced leukocyte 
rolling, adhesion and transmigration. In addition, stabilising the native CRP by blocking its dissociation 
using 1,6-bis(phosphocholine)-hexane, abrogated these effects. In our work, we specifically chose the 
murine model as under inflammatory conditions, CRP production is a minor part of the acute response 
to insult-and was not evident within the brains of our transgenic AD mice. Although we did not perform 
stereotactic injection of native CRP in our model, it is likely that it would have undergone a similar fate 
within the brain on contact with cells and tissue dissociating to mCRP and producing a similar effect to 
the mCRP-this would be our hypothesis of how the majority of mCRP may build up within the dam-
aged brain tissue in AD. Further studies should be carried out to detail this. A limitation of the use of 
the murine model here, is that it cannot be used effectively to identify the impact of mCRP for example 
after stroke or vascular injury/traumatic brain injury on pathophysiological AD progression, due to its 
lack of production as an acute phase response protein. A CRP over-expressing animal combined with 
MCAO or other injury model could be used to give a better indication of its role (i.e. + /− mCRP in 
the brain)51 although larger mammalian models would have to be used in order to accurately depict a 
role in chronic neuro-deterioration e.g. the canine model that would provide proof-of-concept leading 
potentially to clinical trials52.
In AD patients, we showed that expression of mCRP, but not native CRP was expressed strongly 
in microvessels but only following ischaemic stroke and in stroke-affected regions. Vessels were 
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also β -amyloid positive in many cases suggesting the presence of small vessel disease and usually 
CD105-positive suggesting abnormal activation and perhaps angiogenesis33,41. Cerebrovascular pathol-
ogy is thought to be a key element associated with AD pathology and in particular, inhibition of angi-
ogenesis, which may be an attempt to re-perfuse hypoxic areas of brain tissue, which may be attributed 
to β -amyloid deposition4. Strong mCRP positivity was observed within plaques-again particularly in 
patients with ischaemic stroke, and in addition, neurons and NFTs in p-tau/Aβ strongly positive regions 
were also stained positive for mCRP. It is interesting that when we examined micro-infarcted areas or 
lacunar strokes from patients with AD, there appeared to be a gradient of expression of mCRP being 
strongest near to the infarct core decreasing to a weak expression approaching regions with the appear-
ance of normal tissue structure. This was concomitant with a greater concentration of p-Tau staining 
and Aβ -positive material.
Therefore, our hypothesis here is that mCRP may provide a causative link between ischaemic 
stroke, micro-infarction/lacunar insult or traumatic brain injury associated with vascular damage and 
inflammation,- and the significantly increased risk of development of dementia experienced within 
this population-based on the findings described above. As there are currently no effective and specific 
mCRP-inhibitors, production of such as small molecule inhibitors/antagonists or blocking antibodies 
could form the basis of a novel therapeutic strategy to inhibit down-stream processing linked to neuro-
degeneration/dementia after stroke.
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